Recognised as the leading cause of nosocomial antibiotic-associated diarrhoea, the incidence of Clostridium difficile infection (CDI) remains high despite efforts to improve prevention and reduce the spread of the bacterium in healthcare settings. In the last decade, many studies have focused on the epidemiology and rapid diagnosis of CDI. In addition, different typing methods have been developed for epidemiological studies. This review explores the history of C. difficile and the current scope of the infection. The variety of available laboratory tests for CDI diagnosis and strain typing methods are also examined.
Introduction
Clostridium difficile is one of the most important nosocomial pathogens in humans. It is responsible for outbreaks of hospitalacquired infection, with symptoms including serious diarrhoea and, in several cases, pseudomembranous colitis and even death. Although the principal risk factors in patients are a history of antibiotic treatment, an age of over 65 years, and prolonged hospitalisation [1, 2] , in recent years, studies have described the bacterium spreading further into the community [3] and an increase in the incidence and severity of nosocomial C. difficile infection (CDI) in North America and Europe [4] . This rise has been attributed to the emergence of new hypervirulent strains, including PCRribotype 027 [5] and PCR-ribotype 078 [6] , which has been associated with antimicrobial exposure. Furthermore, a significant correlation between the lack of PCR-ribotype diversity in healthcare settings and greater antimicrobial resistance has been observed [7] .
In the past years, several studies and guidelines have been published to compare CDI incidence among different clinical settings, to increase the awareness of C. difficile and to improve the diagnosis and management of the infection [8] . This review is intended to describe the history of C. difficile, starting from the first descriptions up to the present, including the current knowledge regarding the detection, typing methods, and laboratory diagnosis of CDI.
Clostridium difficile discovery and its early history in humans
C. difficile was first identified by Hall and O'Toole in 1935, in a study of the daily microbial changes in the faeces of ten normal breast-fed infants up to the tenth day, when they left the hospital. The bacterium was described as a strict anaerobe with subterminal, non-bulging, elongate spores. In recognition of the difficulty of its isolation and study, it was originally named Bacillus difficilis [9] . Another remarkable property was its pathogenicity. Some strains were capable of producing toxins and caused respiratory death, with marked edema in the subcutaneous tissues of guinea pigs, rabbits, cats, dogs, rats and pigeons and convulsions in guinea pigs similar to those of tetanus. Its toxin was thermolabile, being inactivated in 5 min at 60 C, but was not absorbed from the intestinal tract of the guinea pig, rat and dog: it acted only upon injection into the tissues [10] . In 1938, the bacterium B. difficilis was reclassified into the genus Clostridium [11] and C. difficile nomenclature was adopted by the Approved List of Bacterial Names [12] .
Between 1940 and 1962, only two studies in the literature refer to C. difficile in humans [13, 14] . However, there was no evidence in these cases that C. difficile was pathogenic. In the 1970s, a number of reports focused on the isolation of C. difficile from different hospitalised cases [15e21], but there did not seem to be an obvious pathogenic role in these cases, and C. difficile was still considered to be part of the normal faecal flora of humans. During this period, the first studies in animal models were published [22, 23] . One of these studies [23] reported a cytopathic toxin in tissue-cultured cells and suggested the activation of an uncultivated virus. However, in retrospect, these findings could represent a description of the cytopathic effect of C. difficile induced by its toxins [24] .
Pseudomembranous colitis (PMC) was first described in 1893 [25] , prior to the availability of antibiotics, as a post-operative complication of gastrojejunostomy for an obstructive peptic ulcer in a young woman. Ten days after surgery, the patient developed haemorrhagic diarrhoea and died. After autopsy, the disease was identified as diphtheric colitis [26] . In subsequent years, many other early cases of PMC were recorded after surgical operations, in particular for patients with obstructive colorectal carcinoma [27] or under antimicrobial therapy [28e30]; however, while many studies showed important clues, its association with C. difficile would not occur until 1978 [31e36] . The finding was reported by three studies that were published in the literature almost simultaneously. In March 1978, one study [37] suggested that C. difficile was the causative agent of PMC. The authors found high titres of toxin in the faeces of all patients with PMC studied and hypothesised that the bacterium might be present in small quantities in the intestines of healthy adults and that under the appropriate conditions, it was able to multiply and cause postoperative diarrhoea or PMC due to its potential for toxin production. In April 1978, a second study [38] reported the isolation of C. difficile from the faeces of a patient with clindamycin-associated PMC and demonstrated both the presence of a faecal toxin and the toxigenicity of the isolate using a tissueculture assay. In May 1978, a third study [39] reported that C. difficile was responsible for PMC and that previous antibiotic therapy produces susceptibility to infection, presumably as a result of a change in the bacterial flora. Finally, in late 1978, it was demonstrated that vancomycin eliminates toxin-producing C. difficile from the colon and is associated with rapid clinical improvement in patients with pseudomembranous colitis [40] . Fig. 1 summarises the early history of C. difficile in humans.
Since then, the number of reports documenting C. difficile infection in hospitals increased, and it became the pathogen of the 90s [41] . In the early 2000s, a rise in the incidence, severity and mortality rate of CDI was reported in Europe and North America, associated with the emergence of a new hypervirulent strain, PCRribotype 027 [5] . C. difficile is now a worldwide public health concern, as it is considered the major cause of antibiotic-associated infections in healthcare settings. Three previous reviews have addressed the recent epidemiology of CDI in hospitals, nursing homes and in the community as well as the principal outbreaks reported [2, 42, 43] .
In recent years, with the availability of next-generation sequencing technologies, it has been demonstrated that C. difficile is closely related to the Peptostreptococcaceae family. It has therefore been suggested that C. difficile should be attributed to a new Peptoclostridium genus, renaming C. difficile to Peptoclostridium difficile. The newly proposed genus, Peptoclostridium, are Grampositive, motile, spore-forming obligate anaerobes. All strains are mesophilic or thermophilic, grow in a neutral to alkaline pH and are oxidase-and catalase-negative. The G þ C content of the genomic DNA ranged from 25 to 32 mol % [44] .
The scope of CDI
C. difficile intestinal colonisation can be asymptomatic or produce disease. The clinical manifestations of CDI range from mild or moderate diarrhoea to fulminant pseudomembranous colitis [8] .
Other symptoms described are malaise, fever, nausea, anorexia, the presence of mucus or blood in the stool, cramping, abdominal discomfort and peripheral leucocytosis. Extraintestinal manifestations (arthritis or bacteraemia) have been described but are rare. Severe disease can present colonic ileus or toxic dilatation and distension with little or no diarrhoea. The worst outcome of CDI is sepsis and death [8] , which is estimated to occur in 17% of cases; however, this percentage is higher among older people [45] .
Antibiotic treatment [1] and advanced age have classically been associated with C. difficile infection and related to an increased mortality rate [46] . A recent review regarding CDI cost-of-illness describes a mean cost ranging from 8911 to 30,049 USD for hospitalised patients (per patient/admission/episode/infection) in the USA [47] . In Europe, the annual economic burden is estimated to be approximately 3000 million euro [48] . However, it is necessary to note that the diagnostic strategy remains suboptimal in a large number of healthcare facilities, and a significant proportion of infections may remain undiagnosed [49] .
Colonisation by non-toxigenic C. difficile has also been described, with a prevalence ranging between 0.4% and 6.9% [50] , although this prevalence is lower than the estimated asymptomatic colonisation by toxigenic strains, which is between 7% and 51% [51, 52] . Furthermore, it has been hypothesised that asymptomatic carriers can be colonised by both types of strains (toxigenic and non-toxigenic) for long periods of time without developing the disease [53] . However, these asymptomatic carriers could play an important role in transmission as a source for many unexplained cases [54] . It has been suggested that the presence of non-toxigenic C. difficile in the intestinal tract protects against CDI, although there is no clear evidence to explain how these avirulent strains reduce the risk of developing an infection [50] . Simple competition for a niche in the gastrointestinal tract or other complex effects on mucosal immunity and nutrient acquisition have been hypothesised [50] . A variation in C. difficile non-toxigenic colonisation with age has been described, ranging from 6.9% for patients aged 60 years or more [55] to 22.8% for patients younger than 20 years of age [56] , and up to 53e96% in neonatal units [57, 58] , supporting the hypothesis that these strains are more prevalent in younger patients and infants [50] .
C. difficile outside Europe and North America
As previously cited, C. difficile is the most frequent bacteria associated with nosocomial diarrhoea in Europe and North America. However, little information is available regarding the extent of the infection in other regions or developing countries. In Zimbabwe, a study conducted in a healthcare centre reported a prevalence of 8.6% in a total of 268 diarrhoeal stool samples. Further characterisation of the isolates showed that all were susceptible to metronidazole and vancomycin, but approximately 70% were resistant to co-trimoxazole, which is an antibiotic widely used in this region as prophylaxis against infections in HIV/AIDS patients [59] . In a study of the gut microbiota of 6-month-old Kenyan infants consuming home-fortified maize porridge daily for 4 months and receiving micronutrient powder containing 2.5 ng of iron, C. difficile was detected with a high prevalence (56.5%). The results obtained showed that iron fortification in infants adversely affected the gut microbiota, with an increase in the proportion of some pathogenic bacteria, including Escherichia coli, Salmonella, Clostridium perfringens and C. difficile [60] . A review [61] on the epidemiology of C. difficile in Asia shows that infection occurred at similar rates to other areas but with a predominance of variant toxin A and toxin B positive strains, including PCR-ribotypes 017 and 018. In contrast with the situation in America and Europe, PCR-ribotypes 027 and 078 have rarely been reported in Asia. The unregulated use of antibiotics in some Asian regions and the lack of surveillance raise concerns over the risk of bacterial mutation and infection [61] . An additional review describes the situation in Thailand in detail. A lack of data regarding C. difficile epidemiology is reported along with a high level of indiscriminate use of antimicrobials. C. difficile strains isolated from Thai patients showed a high degree of resistance for a wide range of antibiotics, including clindamycin, cefoxitin and erythromycin. Nevertheless, the strains were fully susceptible to metronidazole and vancomycin. In the same review, the authors concluded with the recommendation for a monitoring plan for C. difficile infections in hospital and community settings in Thailand and other Asian countries [62] . The same observation has been made for Latin America, where little data are available regarding the epidemiology of C. difficile in hospitals, and increased awareness and vigilance among healthcare professionals and the general public seem essential [63] . In an epidemiological study of C. difficile-associated diarrhoea in a Peruvian hospital, the reported overall incidence per 1000 admissions was 12.9. As the presence of another patient with CDI in the same room was significantly associated with the development of diarrhoea, the authors concluded that C. difficile transmission commonly occurred in this healthcare setting and highlighted the need for implementing adequate hygiene programmes [64] (Table 1) . One of the most serious human health problems in developing regions is the microbial contamination of drinking water and foods, leading to severe gastrointestinal diseases that are exacerbated by under-nutrition and the lack of medical treatment in these regions. Water-, sanitation-and hygiene-related deaths occur almost exclusively in developing countries (99.8%), of which 90% are the deaths of children [65] . Indeed, children are the most at-risk group, especially in the first year of life. C. difficile was identified among a large number of bacteria associated with diarrhoea in this population. However, the source of contamination (water, food or environment) by the enteropathogens identified in diarrheic children was not elucidated [65] .
Another issue of concern is CDI in immuno-compromised patients in developing countries. In a study conducted to assess the microbial aetiologies of diarrhoea in adults infected with human immunodeficiency virus (HIV) in India, C. difficile was the most common bacterial pathogen identified, with a reported prevalence of 18% [66] . Consistent with this study, HIV-positive inpatients and outpatients in Nigeria were shown to be C. difficile-positive in 43% and 14% of cases, respectively [67] (Table 1 ). Both studies show the importance of establishing controlled and regulated access to antibiotics in developing countries, as well as the importance of the early diagnosis of intestinal pathogens to reduce morbidity and mortality rates, especially among HIV-positive people. In a further study evaluating CDI in travellers, infection was reported to be more commonly acquired in low-and middle-income countries. Furthermore, CDI was often acquired in the community by young patients and associated with the empirical use of antimicrobials, frequently fluoroquinolones [68] .
C. difficile is found everywhere
C. difficile is ubiquitous in the environment, and the bacterium has the capacity to persist on inanimate surfaces for as long as several months [69] . These contaminated areas can contribute towards C. difficile transmission in healthcare settings. Bed frames, floors or bedside tables have been described as the most commonly contaminated areas in rooms used to isolate patients with C. difficile diarrhoea [70] , even after detergent-based cleaning [71] . Table 2 summarises the available studies in the literature regarding the dissemination of C. difficile spores in healthcare settings and related environments. However, the difference in prevalence among studies may be due to the sampling and culture methods used [70] and in the cleaning programmes used to control the spread of C. difficile. In this context, a previous study reported that unbuffered hypochlorite (500 ppm) was less effective than phosphate buffered hypochlorite (1600 ppm) for surface decontamination [72] . In addition to the patient room environment, the bacterium was isolated from the hands and stools of asymptomatic hospital staff and from the home of a patient suffering CDI. Furthermore, C. difficile inoculated onto a surface (floor) has been shown to persist there for five months [73] . In an intensive care unit, an outbreak of pseudomembranous colitis was attributed to the cross-contamination of inanimate environmental sources with persistence in the hospital for several weeks [77] . Regarding the medical equipment, two previous studies have reported that the replacement of electronic thermometers with single-use disposables significantly reduced the incidence of C. difficile-associated diarrhoea in both acute care and skilled nursing care facilities [78, 79] . However, it has also been reported that with the use of disposable or electronic thermometers, there was no effect on either the overall rate of nosocomial diarrhoea or the rate of nosocomial infections [79] . A further study also describes how the use of tympanic thermometers reduces the risk of acquiring vancomycin-resistant Enterococcus and CDI by 60% and 40%, respectively [80] .
Increased interest in the transmission of C. difficile has led to new studies in the literature reporting the presence of spores in other areas never studied before. Medical staff has increasingly used mobile technology devices in hospitals, such as iPads, to access electronic patient information. A recent study [82] evaluated the contamination of 20 iPads by C. difficile spores in a healthcare setting. Although with the number of samples tested, there was not sufficient data to estimate the prevalence, and in addition, there was no C. difficile recovery, the study also reported the effect of different agents on iPad disinfection. The results showed that bleach wipes were able to remove the inoculated spores completely from the screen surface, while a microfibre cloth was more effective than alcohol wipes. As there are no existing medical guidelines specific to electronic devices, and the manufacturer recommends avoiding the use of chemicals or abrasives to clean the device, the authors emphasised the importance of reducing the tablets' environmental contact in rooms housing patients suffering from CDI.
There are few studies describing the presence of C. difficile in the natural environment and in the environment in the community (Table 3 ). The prevalence of C. difficile was recently studied in retail baskets, trolleys, conveyor belts and plastic bags in 17 different supermarkets from 2 cities in Saudi Arabia. The study reported a C. difficile prevalence of 0.75% on sampled surfaces, with the highest level of contamination in baskets and trolleys, which could suggest the need for the implementation of planned disinfection in supermarkets to control community-acquired CDI [83] . In the natural environment, the bacterium was detected in seawater, zooplankton [84] , tropical soils [85] and rivers [86] . In the rural environment, C. difficile was recovered from homestead soils, household-stored water [87] and soils of stud farms with mature horses [88] . In this last study, C. difficile was inoculated in equine faeces and the bacterium was found to survive at least 4 years (no later time points were tested) when kept at room temperature and outdoors at an ambient temperature over the year.
While C. difficile is also known as an enteric pathogen in some food-producing and companion animal species, there are several reports describing the presence of the bacterium in the intestinal contents of apparently healthy animals (Table 3) . Moreover, recently published data suggests that animals are an important source of human CDI that can spread disease through environmental contamination, direct or indirect contact, or food contamination, including carcass and meat contamination at slaughter or, in the case of crops, through the use of organic animal manure [129] . Table 3 summarises the prevalence of C. difficile reported in pets (dogs and cats), food animals (pigs and cattle), horses and wild animals. Despite the large number of studies describing the presence of human epidemic PCR-ribotypes in these animals, C. difficile has not been confirmed as a zoonotic agent, but it seems evident that there is a potential risk of transmission, especially in people with close contact with contaminated animals and their environment.
C. difficile characteristics and its toxins
Since its discovery in 1935, the characteristics of C. difficile growth, sporulation and virulence have been documented in detail. The fundamental aspects of the bacterium are summarised in Table 4 . One of these characteristics is that C. difficile has no protease, phospholipase C or lipase, but it is among the few bacteria able to ferment tyrosine to p-cresol, which is a phenolic compound that inhibits the growth of other anaerobic bacteria [134, 20] . Dawson et al. (2008) [134] found that Clostridium sordellii tolerated p-cresol but did not produce it. Therefore, the authors suggested that the mechanism of tolerance might not be linked to the production of this organic compound. Furthermore, the increased production and p-cresol tolerance of some strains, including PCRribotype 027 strains, has led to hypotheses regarding its contribution towards C. difficile hypervirulence [134] .
C. difficile is able to produce two major toxins, toxin A (308 kDa) and toxin B (270 kDa), as well as the binary cytolethal distending toxin (CDT). Toxins A and B belong to the group of Large Clostridial Toxins (LCT). Only strains that produce at least one of the three toxins cause disease. Toxin A is considered to be an enterotoxin because it causes fluid accumulation in the bowel. Toxin B does not cause fluid accumulation but is extremely cytopathic for tissuecultured cells [130] . These toxins are encoded by two genes, tcdA and tcdB, mapping to a 19.6 kb pathogenicity locus (PaLoc) and containing 3 additional regulatory genes, tcdC, tcdR, and tcdE, that are responsible for the synthesis and regulation of toxins A and B [135] . Deletions, insertions, or polymorphic restriction sites in one or more of the PaLoc genes can result in toxin variant strains that produce either toxin A or toxin B [135] . While the power of purified toxin A to produce pathology in vitro has been widely described, a study [136] reported that toxin B, but not toxin A, was essential for virulence. Finally, in 2011, it was shown that both mutant variants, toxin Aþ toxin BÀ and toxin AÀ toxin Bþ, can cause disease [137] . It is worth noting that toxin A þ BÀ isolates of C. difficile have not been described in nature. Toxin AÀ toxin Bþ strains have been widely reported in human cases [138] but also in animals suffering from diarrhoea [139] . A previous study reported that toxin AÀ toxin Bþ strains caused the same spectrum of disease that is associated with toxin Aþ toxin Bþ strains, ranging from asymptomatic colonisation to fulminant colitis, with outbreaks in hospitals and other healthcare settings worldwide [135] . It must be noted that toxin AÀ toxin Bþ strains are sometimes reported solely on the basis of the lack of tcdA amplification; however, there are some Aþ variant strains with a partially deleted tcdA fragment [140] . Both toxins A and B translocate to the cytosol of target cells and inactivate small GTP-binding proteins. By glycosylating small GTPases, the two toxins cause actin condensation and cell rounding, which is followed by cell death. Toxin A acts primarily within the intestinal epithelium, while toxin B has broader cell tropism [141] . Both toxins induce the production of tumour necrosis factor alpha and pro-inflammatory interleukins, which induce the inflammatory cascade and the pseudomembrane formation in the colon. The endoscopy of C. difficile colitis shows a colonic mucosa with multiple whitish plaques, usually raised and adherent, of a size varying from a few millimetres to 1e2 cm; the cells can even be confluent in severe disease. The intervening colonic mucosa can be oedematous, granular, hyperaemic or completely normal [142] .
The genes cdtA and cdtB, encoding the CDT, which belongs to the group of clostridial binary toxins, are not found on the PaLoc. This toxin is encoded on a separate region of the chromosome (CdtLoc). It has been described that all strains with cdtA and cdtB genes are variant strains (with changes in the tcdA and tcdB genes) [143] . In contrast, most types not producing binary toxin have toxin genes very similar to the reference strain, VPI 10463.
1 These CDT þ strains represent up to 6% of the toxigenic isolates from hospitalised patients [143] . The production of CDT is frequently associated with hypervirulent strains. CDT has been described as causing the collapse of the actin cytoskeleton and cell death. The lipolysisstimulated lipoprotein receptor (LSR) is known to be the host receptor for the C. difficile CDT toxin [144] . Furthermore, the CDT toxin also induces the formation of microtubule-based protrusions and increases the adherence of the bacterium [145] . While CDT is still being investigated, some studies have already reported data regarding the clinical relevance of this toxin. Bacci et al. (2011) [146] associated the presence of CDT in patients with higher case-facility (death) rates. Other authors also found that CDT was a marker for more virulent C. difficile strains or that it contributed directly to strain virulence. Tagashira et al. (2013) [147] described two cases of fulminant colitis due to CDT þ strains in the same ward of a hospital in Japan occurring within ten weeks of each other. A further study suggested that CDT was a predictor of recurrent infection, and its presence may require longer antibiotic treatments [148] . CDT þ C. difficile strains that do not produce toxins A and B have been described in independent cases of patients with diarrhoea suspected of having CDI [149] .
Laboratory diagnosis of CDI
To aid in the surveillance of CDI and to increase comparability between clinical settings, standardised case definitions have been proposed (Fig. 2) [8] . A laboratory diagnosis of CDI must be based on the detection of C. difficile toxins or on the isolation of toxigenic C. difficile strains from stool samples [150] . However, these results should be combined with the clinical findings to diagnose the disease. The clinical manifestation includes diarrhoea with the passage of 3 or more unformed stools in 24 or fewer consecutive hours [8] . In this context, only unformed and fresh stools should be tested for diagnostic purposes (the specimen should be loose enough to take the shape of the container). The cytotoxic activity is lost very quickly, meaning if the analysis of fresh specimens is not possible, the samples should be stored at 4 C or below. However, cultures are not affected by temporal conditions due to sporulation [150] . Formed stools only must be tested if they come from patients with ileus or potential toxic megacolon or in the case of epidemiological studies [150] .
A recent guide to the utilisation of the microbiology laboratory for the diagnosis of infectious diseases [151] highlights the importance of the collection device, temperature and transport time because the interpretation of the results will depend on the quality of the specimens received for analysis. Specifically, regarding C. difficile, the recommendations are that the stool samples must be received in sterile close containers and kept at room temperature for a maximum of 2 h, and therefore, specimens of dubious quality must be rejected [151] . The culture of samples is recognised as the most sensitive method for the detection of C. difficile, but its specificity for CDI is low because the rate of asymptomatic carriage of C. difficile among hospitalised patients is so high. This method is not clinically practical for routine diagnosis because it does not distinguish between toxigenic and non-toxigenic isolates and requires 24e48 h to obtain the first results [150] . However, stool culture testing permits the molecular typing of the isolated strains and antibiotic susceptibility determination, making it essential for epidemiological surveys [8, 150] . Therefore, stool culture testing can be coupled with a cell cytotoxicity assay or EIA (enzyme immunoassay) to detect toxinproducing C. difficile strains (known as toxigenic cultures), resulting in increased specificity [150] .
Since it was first proposed by George et al. in 1979 [133] , cycloserine-cefoxitin fructose (CCF) has been the most commonly used medium for C. difficile isolation. The original formulation has been extensively modified, including the replacement of egg yolk by blood [150] . The addition of 1 g/L of taurocholate, desoxycholate or cholate has also been shown to induce the germination of C. difficile spores when they are incorporated in CCF [152, 153] . Sodium salt of cholic acid is more inexpensive than pure taurocholate but just as effective [150] . The concentration of the selective agents has also varied among studies, from 250 mg/L to 500 mg/L for cycloserine and from 8 mg/L to 16 mg/L for cefoxitin. Other modifications to improve this media have been proposed. Delm ee et al. [154] included cefotaxime instead of cefoxitin, which increased the sensitivity and specificity of the medium. C. difficile colonies are easily recognised in this media when observed under the microscope: with an appearance similar to ground glass, they release an odour akin to horse manure and reveal a yellow-green fluorescence under ultraviolet illumination. Early identification of C. difficile colonies in this primary selective culture can be performed using an antigen latex agglutination assay. Latex particles are coated with IgG antibodies specific to C. difficile cell wall antigens. When the bacterium is present, the latex particles agglutinate into large visible clumps within 2 min. However, cross-reactions have been described, including with C. sordellii, Clostridium glycollicum and Clostridium bifermentans [155] .
Presently, several commercial selective media are available for the detection of C. difficile from stool specimens. The new chromogenic media seem to be effective as well as more rapid and sensitive than the classic selective media and have been shown to aid in the diagnosis of CDI [156e159]. However, pre-made agars are expensive and unaffordable for many research groups. Furthermore, they are used for the clinical recovery of C. difficile from faecal samples and not for the semi-quantification of viable spores [160] .
Pre-treatment of samples with ethanol shock has been associated with an increase in sensitivity [161e164]. However, in the different studies conducted in our laboratory (unpublished data), ethanol shock or pre-heat treatment of samples does not improve the recovery of C. difficile from faecal or food samples. Rather, it seems that an increase in the time of enrichment is best for improving the sensitivity of the method. A bacterial competition in the enrichment broth has been observed [164] . In a previous study on carcasses and faecal samples [116] , after 30 days of enrichment, different C. difficile types were identified, and colonies other than C. difficile were rarely present in the plate. However, the enrichment of samples is a time-consuming technique for laboratory purposes and might not be worth the slight increase in sensitivity observed.
Toxin detection is the most important clinical test [8] . It can be performed using cell lines to examine a stool filtrate (cell cytotoxicity assay) or by EIA [150] . Cell cytotoxicity is often considered the best standard test for identifying toxigenic C. difficile as it can detect toxins at picogram levels and is recognised as the most sensitive available test for the detection of toxin B [165] . A laboratory cell line (Vero, Hep2, fibroblasts, CHO or HeLa cells) is exposed to a filtrate of a stool suspension. If C. difficile toxins are present, a cytopathic effect is observed after 24e48 h (cell rounding via cytoskeleton disruption). The effect is mainly due to toxin B, which is more cytotoxic than toxin A. The presence of toxigenic C. difficile can be confirmed if a specific antiserum (added later) reverses the effect on the cells. This method is very sensitive and specific but is relatively slow and requires the maintenance of cell lines. If the antiserum does not neutralise the cytopathic effect, which is observed in 21% of cases, the results are inconclusive [150] .
EIA is rapid but less sensitive than the cell cytotoxicity assay [8] , missing 40% of diagnoses [165] . However, it is easy to perform and does not require technical training or special equipment. EIA can detect both toxin A and toxin B and may also detect glutamate dehydrogenase (GDH), a specific enzyme of C. difficile found in toxigenic and non-toxigenic isolates. C. difficile constitutively produces GDH in easily detectable levels, so tests based on GDH detection have good sensitivity (96%e100%). As GDH only identifies the bacterium and not the presence of toxins, the method is comparable with stool culture. Furthermore, it only takes 15e45 min and the cost is low (estimated at 8 USD); it can also be combined with a cell cytotoxicity assay, EIA for toxins, or culture with further toxin characterisation of the strains [165] . However, the results from GDH seem to differ based on the commercial kit used, and therefore, for some authors, this approach remains an interim recommendation [8] . EIA may be useful in laboratories without tissue culture facilities, but it must be combined with a positive culture. If the EIA results are negative and the culture test results are positive, it is recommended to isolate the strain from the plate and repeat EIA testing to determine if it is toxigenic [150] . Table 5 summarises the most-used tests for the diagnosis of C. difficile infection.
Delm ee et al. (2001) [150] proposed the following scheme for the routine bacteriological diagnosis of CDI in humans. First, culture and toxin detection (by cytotoxicity assay or by EIA) should be performed directly from the stool specimen. If both tests are negative, a diagnosis of CDI is excluded. In contrast, if both are positive, the patient is diagnosed with CDI and requires immediate treatment. When the culture is positive but toxin detection is negative, an EIA test should be performed on several colonies removed from the culture plate. If the test is still negative, treatment is not necessary. If the test is positive, the patient should be considered positive for CDI. Finally, when the culture is negative but toxin detection is positive, a control specimen is requested and the culture must be repeated, which results in a patient testing positive for C. difficile in most cases. Repeat testing of patients who were previously positive as a "test of cure" is not appropriate [150] .
Many studies have developed different real-time PCR (RT-PCR) methods for the detection of C. difficile toxin genes directly from stool samples, not only from humans [166, 167] but also from animals [168] , and for the quantitative detection of C. difficile in hospital environmental samples [169] . Various automated RT-PCR systems are commercially available, intended as diagnostic tools for CDI. These systems include BD GeneOhm™ Cdiff (Becton Dickenson) 2 and Xpert ® C. difficile (Cepheid). 3 These commercial RTPCRs have been shown to be rapid (<4 h for a result), sensitive and specific. Therefore, they have been largely proposed for the laboratory diagnosis of CDI [170e172] . In addition, a recent guide for the management of C. difficile infection in surgical patients suggests that PCR testing of perirectal swabs may be an efficient method for toxigenic C. difficile detection [173] . There are several other molecular genetic test systems commercially available for the identification of C. difficile from stool and culture samples. One example is Genotype Cdiff (Hain Lifescience), which is based on DNA strip technology. 4 This system is based on DNA amplification, hybridisation and visualisation using the enzyme alkaline phosphatase. The results are visible in a colorimetric reaction. The test is rapid in detecting C. difficile, its toxins, deletions in the tcdC gene, and mutations in the gyrA gene that are associated with moxifloxacin resistance. However, these new technologies require considerable capital equipment, costly cartridges and experienced laboratory personnel. Furthermore, the results reported have not shown any significant improvement when compared with classic methods [150] . Therefore, some laboratories use these procedures to verify dubious results observed after rapid screening with other methods or to further process the samples for epidemiological purposes.
C. difficile typing methods
To characterise and compare the circulating strains and to identify emerging strains and those responsible for outbreaks worldwide, several typing methods have been applied. Table 6 summarises the available typing methods and their advantages and disadvantages. Lem ee et al. (2004) [140] designed a multiplex PCR for the simultaneous identification and toxigenic type characterisation of C. difficile isolates. Several other studies have proposed different multiplex PCR primers and protocols not only to detect the genes encoding the major toxins A and B but also to detect binary toxin genes (cdtA and cdtB) and other deletions in the Paloc genes [174] .
Pulsed-field gel electrophoresis (PFGE 5 ) and restriction enzyme analysis (REA) are widely used in the United States and Canada. PFGE was one of the first molecular methods used for C. difficile and other food-borne pathogens in North America [175] . The method uses restriction enzymes that infrequently cut (such as SmaI or SacII) to cleave bacterial DNA at different restriction sites. The use of these infrequently cutting restriction enzymes limits the number of restriction fragments (to between 7 and 20) and ensures that they are relatively large [176] . Generally, the frequency of cutting is inversely proportional to the number of nucleotides in the recognition site [177] . In North America, the isolates are designated with NAP and a number (e.g., NAP1: North America Pulsotype 1) [178] . The technique separates the large fragments of DNA generated based on size using a pulsed-field electrophoresis gel with resulting electrophoresis patterns that are highly discriminatory. However, large amounts of high-molecular-weight DNA have to be read, making the process labour-intensive (Table 6 ). C. difficile typing based on REA is performed using total cellular DNA, which is digested with a frequently cutting restriction enzyme (HindIII), and the resulting fragments are resolved by classical agarose electrophoresis. This method was shown to be reproducible, highly discriminatory and universally applicable. However, the visual assessment of the large number of fragments in a single gel can be difficult and may be confounded by the presence of extrachromosomal DNA [175] (Table 6 ).
In Europe, C. difficile PCR-ribotyping has been recognised as the dominant typing method. PCR-ribotyping is based on the size variation of the 16Se23S rDNA intergenic spacer regions. A PCRribotype is defined as a group of strains that produce an identical band pattern. Therefore, a single band difference warrants a new ribotype [178] . Stubbs et al. (1999) [179] constructed a C. difficile PCR-ribotype reference library composed of 2030 isolates, with a total of 116 distinct types identified from environmental, hospital, community practitioner, veterinary and reference sources. The method was performed with agarose gel-based electrophoresis. Bidet et al. (1999) [180] improved the reading of the banding patterns by selecting a partial sequence of the rRNA genes (16Se23S) and the intergenic spacer region with a new set of primers located closer to this intergenic spacer region. The Public Health Laboratory 2 https://www.bd.com/resource.aspx?IDX¼17953. 3 http://www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/healthcareassociated-infections/xpert-c-difficile. 4 http://www.hain-lifescience.de/en/products/microbiology/genotype-cdiff/ genotype-cdiff.html. a https://www.bd.com/resource.aspx?IDX¼17953. b http://www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/healthcare-associated-infections/xpert-c-difficile. c Specific enzyme of C. difficile produced in in both toxigenic and non-toxigenic isolates. d Low specificity for C. difficile infection (CDI) because the rate of asymptomatic carriage of C. difficile among hospitalised patients is so high. e They have been largely proposed for laboratory diagnosis of CDI but also for quantitative detection of C. difficile in hospital environmental samples. Random amplification of DNA segments by PCR reaction using a single primer of arbitrary nucleotide sequence Inexpensive Does not require any specific knowledge of the DNA sequence Must be combined with PCR-ribotyping to obtain higher discriminatory power [193, 194] Amplified fragment length polymorphism (AFLP) Genomic DNA is totally digested with two restriction enzymes. This step is followed by ligation of doublestranded oligonucleotide adaptors to the sticky ends of the restriction fragments followed by amplified by PCR
Low cost
Suboptimal reproducibility (variation in the precision of sizing of fragments) Limited application in C. difficile typing [195] Toxinotyping Polymerase chain reaction-restriction fragment length polymorphism based method for differentiating strains according to changes in their toxin genes when compared to the reference VPI 10463 strain
Results of toxinotyping and PCR-ribotyping correlated well
Requires technical skills [175] Multilocus sequence typing (MLST)
The sequences of internal fragments of housekeeping genes (usually seven) are used to characterise the strains Inter-laboratory comparisons easy Time-consuming (several days) Costly and laborious technique Requires specific technical skills [199, 200] Multilocus variable number tandem repeat analysis (MLVA)
The method utilizes the naturally occurring variation in the number of tandem repeated DNA sequences found in many different loci in the genome. The different lengths of variable number of tandem repeats (VNTR) regions are determined to distinguish among strains High discriminatory power which allows tracking of outbreaks and determining phylogenetic relationships
Time-consuming Costly and laborious technique Requires specific technical skills
Inter-laboratory comparisons difficult [175, 201] Whole genome sequencing (WGS)
The method reveals the complete DNA of the bacterium at a single time
Provides the most comprehensive collection of an individual's genetic variation Increasingly low cost
Method still under development The large amount of data requires technical skills for further processing and analysis [203] a Species species-interspecific fragment of the triose phosphate isomerase (tpi) housekeeping gene.
Service Anaerobe Reference Unit, Cardiff (UK) has established a ribotyping nomenclature reference database for C. difficile. This nomenclature is designated by a three-digit number starting from 001 (ex. PCR-ribotype 027). Currently, the collection of existing PCR-ribotypes and the assignment of new ones is performed by the Health Protection Agency-funded C. difficile Ribotype Network (CDRN) in Leeds (UK), which has more than 600 different PCRribotypes in the CDRN database [181] . However, in many laboratories, the standard nomenclature is not always available and a local nomenclature is used, making inter-laboratory comparisons difficult [178] (Table 6 ). Indra et al. (2008) [182] developed a C. difficile sequencer-based PCR-ribotyping method based on capillary gel electrophoresis that was proposed in order to solve the problems associated with inter-laboratory comparisons of typing results and to make PCR-ribotyping less time-intensive (Table 6 ). PCR amplification was performed using a fluorescent label in one of the primers, and the amplicon sizes were determined using an ABI genetic analyser [175] . A database and web-based software programme was created that allows the analysis and comparison of C. difficile capillary-sequencer-based PCR-ribotyping data by simply uploading sequencer data files. 6 Janezic et al. (2011) [183] described a modification to PCR-ribotyping that enables the detection of C. difficile in stool samples within hours. The designed primers were located partially within the C. difficile 16Se23S rRNA intergenic spacer regions and partially within 16S (forward primer) and 23S (reverse primer). The QIAxcel ® system has been proposed as a new method for C.
difficile ribotyping, the detection of tcdC18 bp deletion, and toxin gene detection (toxin A, toxin B and binary toxin CDT genes). 7 QIAxcel is based on an automated electrophoresis platform that processes samples in batches of 12 and allows the analysis of up to 96 samples per run. The system does not require the use of fluorescein-labelled primers and displays the data as both a gelview format and an electropherogram. The system has the potential to reduce the cost of PCR-ribotyping by drastically reducing the hands-on time. The major costs are the purchase of cartridges, the setup of the QIAxcel system hardware, and the BioCalculator analysis. However, the method has limited sensitivity and discriminatory power. It cannot clearly distinguish between closely related ribotypes, such as 027 and 176 [184] . Serotyping distinguishes variations in C. difficile strains based on the bacterial surface antigens. Serogrouping by slide agglutination and by polyacrylamide gel electrophoresis have both been traditionally accepted as practical in routine typing [185] . Both methods have shown a good correlation in results and allow the differentiation of 10 major serogroups (A, B, C, D [186] used an enzyme-linked immunosorbent assay (ELISA) with antisera specific for the 10 C. difficile serogroups (A1, B, C, D, F, G, H, I , K, X) and the 12 serogroups within serogroup A (A2 to A12) for the serogrouping of C. difficile colonies for 314 positive faecal samples. The authors found that ELISA was a rapid and reliable method for C. difficile serotyping and that cross-agglutination caused by flagellar antigens in the slide agglutination method is totally suppressed by ELISA.
Surface-layer protein A gene sequence typing (slpAST) has also been described for C. difficile characterisation. C. difficile has a surface immuno-protein Layer (S-layer) encoded by the slpA gene, and the typing of isolates is performed by the sequencing of this slpA gene. It can also be used for direct typing from DNA stool specimens without culture [187] . This method has been reported as a discriminative tool for C. difficile characterisation [188] . However, Dingle et al. (2013) [189] showed that the C. difficile genotype was not predictive of antigenic types. Therefore, S-layer typing could be useful for explaining the temporal changes and geographic differences in the epidemiology of CDI as well as the way in which isolates (and antigens) are selected for inclusion in C. difficile vaccines [189] .
Repetitive sequence-based PCR typing (rep-PCR) is another method proposed for the characterisation of C. difficile strains [190] . Bacterial genomes contain multiple dispersed short repetitive sequences separating longer single-copy DNA sequences. Specific repetitive PCR primers complement these repetitive sequences, and the amplified DNA fragments provide a genomic fingerprint that can be employed for subspecies discrimination [191] . The DiversiLab system 8 is an automated rep-PCR typing method that has a high discriminatory power when compared to traditional PCRribotyping. However, this method requires the visual interpretation of rep-PCR fingerprint patterns and technical skills. Furthermore, interlaboratory reproducibility for this method must be demonstrated prior to its use for C. difficile surveillance [192] . Random amplified polymorphic DNA (RAPD) analysis is the 'random amplification' of DNA segments by PCR reaction using a single primer consisting of an arbitrary nucleotide sequence. RAPD is an inexpensive and powerful typing method and does not require any specific knowledge of the DNA sequence of the target microorganism. The amplification of a segment of DNA will be performed depending on positions that are complementary to the primer sequence. Green et al. (2011) [193] used PCR-ribotyping in conjunction with RAPD to further categorise different C. difficile types within defined PCR-ribotypes and therefore obtained a higher discriminatory power than either of the methods used alone. Barbut et al. (1993) [194] evaluated genomic fingerprinting of C. difficile strains using RAPD and suggested that this method could be an additional valuable tool for epidemiological studies.
In the amplified fragment length polymorphism (AFLP) technique, a small amount of purified genomic DNA is totally digested with two restriction enzymes, one with an average cutting frequency and the other with a higher cutting frequency. This step is followed by the ligation of double-stranded oligonucleotide adaptors to the sticky ends of the restriction fragments, followed by PCR amplification. After final amplification, the selectively amplified fragments are separated by gel electrophoresis and comparison of banding patterns is typically achieved using dedicated fingerprinting analysis software. AFPL has a relatively low cost, but variation in the precision of the sizing of fragments has been observed, leading to suboptimal reproducibility [195] . This method has seen limited application in C. difficile typing. Klaassen et al. (2002) [196] reported that AFLP analysis yielded high-resolution and highly reproducible fingerprinting patterns in a short time period (24 h) to evaluate epidemiological relatedness among hospital C. difficile isolates. A further study showed that AFLP is better able to discriminate between C. difficile reference strains (most of them toxin Aþ, toxin Bþ) than PCR-ribotyping. However, for toxin AÀ, toxin Bþ isolates, both methods yielded similar results [138] .
Toxinotyping is a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) based method for differentiating C. difficile strains according to changes in their toxin genes 6 https://webribo.ages.at/. 7 https://www.qiagen.com/be/products/catalog/automated-solutions/detectionand-analysis/qiaxcel-advanced-system/. 9 . In this context, only one strain resembling VPI 10463 and positive for CDT has been previously described [197] . Toxinotype XXXII has been recently reported and corresponds to a new type of C. difficile strain (toxin AÀ, Bþ, CDT-) that completely lacks the tcdA gene and has an atypical organisation of the PaLoc integration site [198] . Multilocus sequence typing (MLST) analysis uses the sequences of internal fragments of housekeeping genes (usually seven) to characterise the strains. The internal fragments of each gene (450e500 bp) are sequenced on both strands using an automated DNA sequencer. For each housekeeping gene, the different sequences present within a bacterial species are assigned as distinct alleles, and for each isolate, the alleles at each of the seven loci define the allelic profile or sequence type (ST). The data obtained are unambiguous, and the allelic profiles of the isolates can easily be compared to those in a large central database and therefore can be compared between laboratories 10 . There are two MLST databases available for C. difficile, each adapted to a different typing scheme: the first is organised according to the scheme described by Griffiths et al. (2010) [199] , which is performed with the housekeeping genes adk, atp, dxr, recA, sodA, tpi and glyA 11 ; and the second is organised according to the scheme described by Lem ee et al. (2004) [200] , which is performed with the housekeeping genes aroE, dutA, gmk, groEL, recA, sodA and tpi. 12 The primary problem with MLST is the time-consuming nature of the method, with the completion of analysis taking several days. In addition, MLST is a relatively costly and laborious technique that requires specific technical skills. Multilocus variable-number tandem-repeat analysis (MLVA) has been suggested to have higher discriminatory power than other typing methods for investigating the relatedness between C. difficile strains [201] . It has been widely used in medical microbiology as an alternative or complement to other typing techniques such as PFGE, rep-PCR or MLST [202] . MLVA utilizes the naturally occurring variation in the number of tandem repeat DNA sequences found in many different loci in the genome. Therefore, the lengths of the variable number of tandem repeats (VNTR) regions are determined to distinguish among the strains. The technique is achieved by a multiplex PCR assay (with primers designed to target different VNTR regions in the genome) and visualised by electrophoresis or automated fragment analysis on a sequencer. The product size is used to calculate the number of repeat units of each locus. The calculated numbers of repeats of the VNTR loci (alleles) are combined, and this provides the MLVA profile. Each unique MLVA profile is given an MLVA type designation. The MLVA profile can be used for the comparison and clustering of the bacterial strains. 13 Compared with traditional PCR ribotyping, MLVA has increased discriminatory power, which allows for the more efficient tracking of outbreaks and has the potential to determine phylogenetic relationships. In addition, MLVA produces digital data with a decreased turnaround time [175] .
Whole genome sequencing (WGS) reveals the complete DNA of an organism at a single time and provides the most comprehensive collection of an individual's genetic variation [203] . Sanger sequencing and subsequently Roche 454 and Illumina nextgeneration sequencing technologies have been applied to study the evolutionary dynamics of C. difficile [175] at increasingly low cost [203] . Recent studies have applied WGS to determine the epidemiological relationships between C. difficile strains in healthcare settings or in the scientific community employing WGS [204] . Although the method is still under development and the large amount of data obtained requires technical skills for further processing and analysis, it is very probable that in the near future, WGS will replace all other current typing techniques. Killgore et al. (2007) [205] compared seven different techniques (REA, PGE, PCR-ribotyping, MLST, MLVA, AFLP and slpAST) for epidemic C. difficile strain typing. They found that all methods appeared to be adequate for detecting an outbreak strain in a particular institution. However, REA or MLVA showed the highest level of discrimination between strains, and they seem to be the most recommended methods to track outbreak strains geographically. However, as neither of the techniques are widely used and little data are available, there is currently no method with proven interlaboratory reproducibility for inter-institutional C. difficile tracking.
High-throughput sequencing analysis and CDI
16S metagenetics is a culture-independent strategy allowing the identification of bacterial populations present in a large panel of samples. It has been recently introduced to investigate the intestinal microbiota of healthy patients and patients suffering CDI. In the last year, most of the studies reported bacteria at the phylum and class level, but higher taxonomic resolution may reveal more differences in the population structure [206] . Preliminary results have shown that one of the taxa found in high proportions in patients with CDI is Proteobacteria, while Bacteroidetes proportions are lower in infected patients [207] . In this context, one study has proposed the use of Bacteroidetes and Firmicutes as probiotics to treat CDI [208] . However, the few available data regarding alterations to the intestinal microbiota of patients with CDI has been obtained in different patient conditions (age, antibiotic treatment, hospitalisation), which explains the high amount of variability between the studies. Despite this limitation, further studies exploring the diversity of the gut microbiota in CDI patients will be critical for further understanding the pathogenesis of C. difficile and for developing new approaches for the treatment and prophylaxis of the infection. In addition, recent studies in humans and animals have shown that many of the sequences were not identical to sequence entries present in the available databases [209, 210] . Furthermore, among the sequences identical to known entries, the species name was seldom taxonomically defined. As previously reported, these findings underline the complexity of the gut microbiota, stressing the need for further research on taxonomy and functional microbiology [207] .
Conclusions and perspectives
Eighty years after its discovery, C. difficile continues to be the focus of attention in hospitals and an important topic for many research groups worldwide. Recognised as the leading cause of nosocomial antibiotic-associated diarrhoea, the incidence of CDI remains high and in some years has increased, despite the efforts to improve prevention and reduce the spread of the bacterium in 9 http://www.mf.uni-mb.si/tox/. 10 http://pubmlst.org/general.shtml. 11 http://pubmlst.org/cdifficile/. 12 http://www.pasteur.fr/recherche/genopole/PF8/mlst/Cdifficile2.html. 13 http://www.mlva.net/.
healthcare settings. Outside of Europe and America, the incidence of CDI infection is also rising. The major research studies of the last decade have been focused on the control of the spread of the bacterium, the rapid diagnosis of CDI, and the efficacy of treatment and recurrence prevention. Different guidelines have been designed to improve the management of the infection. Diagnosis must consider both clinical and laboratory findings. Laboratory tests must be rapid and sensitive; therefore, stool culture is not clinically practical. However, the isolation of the strain is necessary for epidemiological studies. There is a need for highly discriminatory typing methods, and results should be comparable between laboratories. One potential alternative in the near future is whole genome sequencing, now considered as the next-generation typing tool.
The investigation of the gut's microbial communities by new metagenetic analyses will allow researchers to discern whether any alteration of the gut microbiota composition can favour C. difficile colonisation, as well as the microbes responsible for rendering individuals less susceptible to the infection. This approach will be critical in the future to further understand the pathogenesis of C. difficile and to develop new successful prevention and treatment measures.
